Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Genomics: Clinical Implementation » Sema4 Nabs New York State Approval for Cancer Somatic Sequencing Tests

Sema4 Nabs New York State Approval for Cancer Somatic Sequencing Tests

Jul 15, 2020
|
staff reporter

NEW YORK ─ Sema4 said on Wednesday that it has secured approval from the New York State Department of Health to conduct its Sema4 Signal Whole Exome/Transcriptome Sequencing (WES/WTS) and PanCancer somatic tests.

The firm said it believes it is the first company with a commercial laboratory to be approved by the NYS DOH for WES/WTS for solid and hematologic malignancies using tumor-normal analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Billion-Pound Sticking Point

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

Advisors Push for More Data

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

Moderna Expects Early Trial Data Next Month

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

Science Papers Explore Contribution of ANXA11 to ALS, Role of Gut Microbiome in Autism Spectrum Disorder

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Grants EUAs for Wren Labs, P23 Coronavirus Tests, Binx Health At-Home Sample Collection Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.